Metastatic pancreatic cancer: from human disease to preclinical modelling.

Metastatic pancreatic ductal adenocarcinoma exhibits high molecular heterogeneity and evades detection, contributing to its status as one of the deadliest cancers with poor patient outcomes.

• Why it matters: Understanding the complex interactions and molecular features of metastatic PDAC is crucial for improving diagnosis and developing targeted therapies, addressing significant gaps in current clinical management.
• What they did: The review synthesizes current knowledge of metastatic PDAC’s clinical features, molecular characteristics, and preclinical models, highlighting the role of tumor-microenvironment interactions and identifying research limitations.
• The result: Advancing insights into these mechanisms can inform the development of precision oncology strategies, potentially leading to more effective treatments and better management of pancreatic cancer metastasis.